Particle.news
Download on the App Store
5 ARTICLES
·
last wk.

Enlighten Protein Blood Test Reaches 450 Participants in UK Multi-Cancer Trial

The MODERNISED study is recruiting 450 participants at five UK sites ahead of Manchester expansion to test the assay’s accuracy in detecting ten cancer types by immune signals.

Image

Overview

  • The MODERNISED trial is assessing Enlighten, a protein-based blood test designed to identify immune response markers linked to ten solid tumours at their earliest stages.
  • Over 450 of the targeted 1,000 participants have been enrolled at hospital sites in Hampshire and Dorset with Manchester set to open soon.
  • Researchers will compare samples from newly diagnosed cancer patients against 350 control samples from symptomatic non-cancer patients and healthy volunteers.
  • Enlighten focuses on detecting proteins released by the immune system rather than circulating tumour DNA and is also being evaluated for its ability to pinpoint tumour origin.
  • Led by the Southampton Clinical Trials Unit and backed by the NIHR Invention for Innovation programme and the Office for Life Sciences, the study’s findings are expected after full recruitment.